Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

KalVista Pharmaceuticals (KALV) Presents Sebetralstat DataSeptember 6, 2024 6:30 AM KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024September 6, 2024 6:30 AM Form 8-K KalVista Pharmaceuticals For: Sep 05September 5, 2024 4:29 PM Form 10-Q KalVista Pharmaceuticals For: Jul 31September 5, 2024 4:14 PM KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 3cSeptember 5, 2024 6:31 AM KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateSeptember 5, 2024 6:30 AM KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2024 6:30 AM